



UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office

Address: COMMISSIONER OF PATENTS AND TRADEMARKS
Washington, D.C. 20231

Ch

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.
09/581,252	12/04/00	MUNROE	P108074-0000

ARENT FOX KINTNER PLOTKIN & KAHN
SUITE 600
1050 CONNECTICUT AVENUE NW
WASHINGTON DC 20036-5339

HM22/0420

EXAMINER

SHIBUYA, M

ART UNIT	PAPER NUMBER
----------	--------------

1635

DATE MAILED:

04/20/01

Please find below and/or attached an Office communication concerning this application or proceeding.

Commissioner of Patents and Trademarks

Art Unit: 1635

Nucleotide and/or Amino Acid Sequence Disclosure

1. This application contains sequence disclosures that are encompassed by the definitions for nucleotide and/or amino acid sequences set forth in 37 CFR 1.821(a)(1) and (a)(2). However, this application fails to comply with the requirements of 37 CFR 1.821 through 1.825 for the following reason(s): A copy of the "Sequence Listing" in computer readable form has not been submitted as required by 37 C.F.R. 1.821(e).

Applicant must provide:


- a. An initial computer readable form (CRF) copy of the "Sequence Listing".
- b. A statement that the content of the paper and computer readable copies are the same and, where applicable, include no new matter, as required by 37 C.F.R. 1.821(e) or 1.821(f) or 1.821(g) or 1.825(b) or 1.825(d).

2. Applicant discloses nucleotide sequences in the drawings (*e.g.*, Figures 3B, 3C, 4B, and 4C) that must be identified by a SEQ ID number, pursuant to 37 CFR 1.821(d), which states: "Where the description or claims of a patent application discuss a sequence listing that is set forth in the 'Sequence Listing' in accordance with paragraph (c) of this section, reference must be made to the sequence by use of the assigned identifier, in the text of the description or claims, even if the sequence is also embedded in the text of the description or claims of the patent application." These sequence identifiers may appear in the drawings themselves, or in the specification's section entitled Brief Description of the Drawings.

Art Unit: 1635

3. Applicant discloses nucleotides sequences in the text, *e.g.*, at pp. 32, 36 of the instant specification, that must be identified by a SEQ ID number.
4. Applicant is required to comply with the above corrections as per above as part of a complete response to this official action.
5. Any inquiry concerning this communication or earlier communications from the examiner should be directed to *Mark L. Shibuya (SRC)*, whose telephone number is (703) 308-9355, and/or to the patent analyst, *Katrina Turner*, whose telephone number is (703) 305-3413.
6. If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, *John LeGuyader* may be reached at (703) 308-0447.
7. Any inquiry of a general nature or relating to the status of this application should be directed to the *Group receptionist* whose telephone number is (703) 308-0196.

Mark L. Shibuya
Patent Examiner
Technology Center 1600
April 11, 2001



JOHN L. LeGUYADER
SUPERVISORY PATENT EXAMINER
TECHNOLOGY CENTER 1600